Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Oncolytics Biotech Inc.NASDAQ: ONCY
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of CA$22.31K rose 17.4% year over year, ahead of the -26.6% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -38.5% a year.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.4% holds above the trailing-twelve-month pace of -26.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
CAD · from the income statement
- Latest · FY2025
- 70K CAD
- Year-over-year change
- -19.5%
- 4-year CAGR
- -33.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70K | -19.5% |
| FY2024 | 2024-12-31 | 87K | -70.9% |
| FY2023 | 2023-12-31 | 298.59K | -0.8% |
| FY2022 | 2022-12-31 | 301.11K | -16.5% |
| FY2021 | 2021-12-31 | 360.58K | — |
Cost of Revenue vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.6% is the 3rd highest of 7, against a peer median of -90.0%.
- Over three fiscal years its annual growth of -38.5% compares with a peer median of -50.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.23M USD | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | $378K USD | +410.8% | +18.3% | 282.1% | |
| LTM Mar 2026 | $151K USD | — | — | — | |
| LTM Mar 2026 | $130.77K USD | — | — | — | |
| LTM Mar 2026 | CA$119.31K CAD | -26.6% | -38.5% | — | |
| LTM Mar 2026 | $65K USD | -83.2% | -45.2% | 0.9% | |
| LTM Mar 2026 | $24K USD | -96.8% | -55.3% | — | |
| LTM Mar 2026 | $16.49K USD | -99.9% | -81.6% | 0.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $5K USD | -100.0% | -71.8% | — |
| Peer median (excluding ONCY) | — | -90.0% | -50.3% | 15.5% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 360.58K | 301.11K | 298.59K | 87K | 70K |
| Gross Profit | (360.58K) | (301.11K) | (298.59K) | (87K) | (70K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M |
| Selling, General & Admin | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M |
| Operating Expenses | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M |
| Depreciation & Amortization | 360.58K | 301.11K | 298.59K | 102K | 96.05K |
| EBITDA | (20.58M) | (18.71M) | (20.19M) | (34.88M) | (39.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.93M) | (20.68M) | (25.04M) | (34.98M) | (39.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 99K | 528K | 1.33M | 1.2M | 529.64K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (15.88K) | 1.67M | 4.55M | 3.4M | 61.75K |
| Income Before Tax | (20.94M) | (19.01M) | (20.49M) | (31.58M) | (39.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39.42K | 64.52K | 71.87K | 130K | 108.4K |
| Net Income | (20.98M) | (19.08M) | (20.56M) | (31.71M) | (39.46M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| EPS (Diluted) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| Weighted Avg Shares | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
| Weighted Avg Shares (Diluted) | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.